Figitumumab in patients with refractory metastatic colorectal cancer previously treated with standard therapies: A nonrandomized, open-label, phase II trial

1. Becerra, C.R.
2. Salazar, R.
3. Garcia-Carbonero, R.
4. Thomas, A.L.
5. Vázquez-Mazón, F.J.
6. Cassidy, J.
7. Maughan, T.
8. Castillo, M.G.
9. Iveson, T.
10. Yin, D.
11. Green, S.
12. Bergsland, E.K.